Publikationer Fredrik Swartling

Publikationer i DiVA

Publikationer i PubMed

Ett urval av våra publikationer

  1. Čančer M, Hutter S, Holmberg KO, Rosén G, Sundström A, Tailor J, Bergström T, Garancher A, Essand M, Wechsler-Reya RJ, Falk A, Weishaupt H, Swartling FJ.  Humanized Stem Cell Models of Pediatric Medulloblastoma Reveal an Oct4/mTOR Axis that Promotes Malignancy. Cell Stem Cell. 25(6):855-870.e11. (2019).

  2. Čančer M, Drews LF, Bengtsson J, Bolin S, Rosén G, Westermark B, Nelander S, Forsberg-Nilsson K, Uhrbom L, Weishaupt H, Swartling FJ. BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cells. Cell Death Dis. 10(12):881. (2019).

  3. Hovestadt V, Ayrault O, Swartling FJ, Robinson GW, Pfister SM, Northcott PA. Medulloblastomics revisited: biological and clinical insights from thousands of patients. Nat Rev Cancer. doi: 10.1038/s41568-019-0223-8. (2019).

  4. Weishaupt H, Johansson P, Sundström A, Lubovac-Pilav Z, Olsson B, Nelander S and Swartling FJ. Batch-normalization of cerebellar and medulloblastoma gene expression datasets utilizing empirically defined negative control genes. Bioinformatics. 35(18):3357-3364 (2019).
     
  5. Bolin S, Borgenvik A, Persson CU, Sundström A, Qi, J, Weiss WA, Cho J-Y, Bradner, JE, Weishaupt H, Swartling FJ. Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma. Oncogene 37:2850-2862 (2018).
     
  6. Suryo Rahmanto A*,1, Savov V*, Brunner AW, Bolin S, Weishaupt H, Čančer M, Rosén G, Hutter S, Sundström A, Kawauchi D, Jones DT, Spruck C, Taylor MD, Maljukova A, Cho YJ, Pfister SM, Kool M, Korshunov A, Swartling FJ*# and Sangfelt O*#. FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma. EMBO J. 35:2192-2212 (2016). 
     
  7. Hill RM, Kuijper S, Lindsey JC, Petrie K, Schwalbe EC, Barker K, Boult JK, Williamson D, Ahmad Z, Hallsworth A, Ryan SL, Poon E, Robinson SP, Ruddle R, Raynaud R, Howell L, Kwok C, Joshi A, Nicholson SL, Crosier S, Ellison DW, Wharton SB, Robson K, Michalksi A, Hargrave D, Jacques TS, Pizer B, Bailey S, Swartling FJ, Weiss WA, Chesler L, Clifford SC. Combined MYC and TP53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease. Cancer Cell. 27(1):72-84 (2015).
     
  8. Swartling FJ#, Savov V, Persson AI, Chen J, Hackett CS, Northcott PA, Grimmer MR, Lau J, Chesler L, Perry A, Phillips JJ, Taylor MD, Weiss WA#. Distinct Neural Stem Cell Populations Give Rise to Disparate Brain Tumors in Response to N-MYC. Cancer Cell. 21(5):601-13 (2012).
     
  9. Persson AI, Petrisch C, Swartling FJ, Melissa I, Goldenberg DD, Vandenberg SR, Nguyen KN, Yakovenko S, Ayers-Ringler J, Thorne CA, Lee E, Nishiyama A, Stallcup WB, Berger MS, Bergers G, McKnight TR, and Weiss WA. Non-stem cell origin for oligodendroglioma. Cancer Cell, 18(6):669-682 (2010).
     
  10. Swartling FJ*, Grimmer MR*, Hackett CS, Northcott PA, Fan QW, Goldenberg DD, Lau J, Masic S, Collins R, Nguyen K, Yakovenko S, Zhe XN, Flynn Gilmer HC, Nagaoka M, Phillips JJ, Jenkins RB, Tihan T, Vandenberg SR, James CD, Tanaka K, Taylor MD, Weiss WA and Chesler L. Pleiotropic role for MYCN in medulloblastoma. Genes and Development, 24:1059-72 (2010).


*, #: delat författarskap/samma medverkan